Edition:
United States

Merus Labs International Inc (MSLI.OQ)

MSLI.OQ on NASDAQ Stock Exchange Capital Market

0.88USD
27 Mar 2017
Change (% chg)

$0.01 (+1.15%)
Prev Close
$0.87
Open
$0.87
Day's High
$0.88
Day's Low
$0.87
Volume
2,276
Avg. Vol
4,519
52-wk High
$1.76
52-wk Low
$0.72

MSLI.OQ

Chart for MSLI.OQ

About

Merus Labs International Inc. is a specialty pharmaceutical company. The Company is engaged in the acquisition and licensing of branded prescription pharmaceutical products. The Company's products include Elantan, Isoket, Deponit, Sintrom, Emselex/Enablex, Surgestone, Provames, Speciafoldine, Tredemine, Salagen, Estraderm MX and... (more)

Overall

Beta: 1.77
Market Cap(Mil.): $102.63
Shares Outstanding(Mil.): 117.35
Dividend: --
Yield (%): --

Financials

  MSLI.OQ Industry Sector
P/E (TTM): -- 29.17 29.94
EPS (TTM): -0.10 -- --
ROI: -5.56 13.48 13.01
ROE: -8.03 14.39 14.16

BRIEF-Merus Labs responds to Reuters News article

* Currently using Rothschild to provide investment banking and financial advisory services

Feb 28 2017

Exclusive: Merus Labs hires Rothschild to explore options - sources

Canadian specialty drugmaker Merus Labs International Inc has hired investment bank Rothschild & Co to explore strategic alternatives, including a potential sale of the company, people familiar with the matter said on Tuesday.

Feb 28 2017

BRIEF-Merus Labs reports fiscal Q1 2017 results

* Continues to expect sintrom related product cost savings during 2017 of about half of full annualized potential of $8 million

Feb 14 2017

BRIEF-BEUTEL, GOODMAN & CO REPORTS 14.12 PCT PASSIVE STAKE IN MERUS LABS

* REPORTS 14.12 PERCENT PASSIVE STAKE IN MERUS LABS INTERNATIONAL INC AS OF DEC 31, 2016 - SEC FILING Source text (http://bit.ly/2iWQuA0) Further company coverage:

Jan 23 2017

More From Around the Web

Earnings vs. Estimates